Sorrento Therapeutics (LTS:0L85) Interest Expense : $-6.81 Mil (TTM As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Sorrento Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sorrento Therapeutics's interest expense for the three months ended in Jun. 2023 was $ -2.67 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2023 was $-6.81 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sorrento Therapeutics's Operating Income for the three months ended in Jun. 2023 was $ -76.77 Mil. Sorrento Therapeutics's Interest Expense for the three months ended in Jun. 2023 was $ -2.67 Mil. Sorrento Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sorrento Therapeutics Interest Expense Historical Data

The historical data trend for Sorrento Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sorrento Therapeutics Interest Expense Chart

Sorrento Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Interest Expense

Get a 7-Day Free Trial

-57.63

-35.05

-20.16

-10.22

-8.57

Sorrento Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Interest Expense	Get a 7-Day Free Trial															-2.31	-0.79	-2.22	-1.13	-2.67

Sorrento Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.81 Mil.

Sorrento Therapeutics (LTS:0L85) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sorrento Therapeutics's Interest Expense for the three months ended in Jun. 2023 was $-2.67 Mil. Its Operating Income for the three months ended in Jun. 2023 was $-76.77 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2023 was $74.19 Mil.

Sorrento Therapeutics's Interest Coverage for the quarter that ended in Jun. 2023 is calculated as

Sorrento Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Sorrento Therapeutics (LTS:0L85) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sorrento Therapeutics Inc (LTS:0L85) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

SRNEQ:USA

Address

4955 Directors Place, San Diego, CA, USA, 92121

Website

https://www.sorrentotherapeutics.com

Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.

Sorrento Therapeutics (LTS:0L85) Headlines

No Headlines